Glycaemic control after continuous glucose monitoring in rural primary-care patients: A pilot feasibility study
Published
January 5, 2025
Paper ID
PAP-000306
Status
Published
DOI
10.65712/tmj.test000564
Advance Services
Abstract
Background: glycaemic control remains a leading cause of avoidable harm among rural primary-care patients. Methods: The primary outcome was glycaemic control, assessed blind to allocation. Results: glycaemic control occurred in 6% of the intervention group versus 16% of controls. glycaemic control occurred in 21% of the intervention group versus 19% of controls. Conclusion: Strengths include the sample size and blinded outcome assessment.
Introduction
Earlier studies of continuous glucose monitoring were small or single-centre. glycaemic control remains a leading cause of avoidable harm among rural primary-care patients. Practice around continuous glucose monitoring varies widely between centres.
Practice around continuous glucose monitoring varies widely between centres. glycaemic control remains a leading cause of avoidable harm among rural primary-care patients. Earlier studies of continuous glucose monitoring were small or single-centre.
Materials and Methods
Eligible participants were rural primary-care patients.
Eligible participants were rural primary-care patients. Missing data were handled with multiple imputation. The primary outcome was glycaemic control, assessed blind to allocation.
Eligible participants were rural primary-care patients. Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.
Analyses were adjusted for age, sex and baseline severity. Missing data were handled with multiple imputation. Eligible participants were rural primary-care patients.
Results
Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.75 (95% CI 0.25 to 0.85). The adjusted odds ratio was 0.61 (95% CI 0.35 to 0.70).
2097 participants were included (median age 34 years). 4197 participants were included (median age 36 years).
2253 participants were included (median age 59 years). Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.69 (95% CI 0.25 to 0.91).
| Group | n | Events |
|---|---|---|
| Age ≥ 65 | 155 | 73 |
| Intervention | 474 | 76 |
| Male | 549 | 119 |
| Age < 65 | 123 | 49 |
| Control | 548 | 43 |
| Female | 471 | 58 |
Values are n (%) unless stated otherwise.

Shown for rural primary-care patients; error bars are 95% confidence intervals.

Shown for rural primary-care patients; error bars are 95% confidence intervals.
741 participants were included (median age 36 years). Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.63 (95% CI 0.31 to 0.68). The adjusted odds ratio was 0.56 (95% CI 0.31 to 0.75).
Discussion
Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.
Strengths include the sample size and blinded outcome assessment. These findings suggest that continuous glucose monitoring is associated with better glycaemic control in rural primary-care patients.
Future work should test continuous glucose monitoring in a pragmatic multicentre trial. Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
Conclusions
Continuous glucose monitoring merits wider use for rural primary-care patients to improve glycaemic control.
References
1. Nakamura X, Kim E, et al. SGLT2 inhibitors and 30-day readmission. Diabetes Care. 2021;334(2):440-1749.
2. Ibrahim O, Mueller X, et al. Delayed cord clamping and post-operative delirium. Eur Heart J. 2018;322(4):115-1342.
3. Novak O, Kim E, et al. Low-dose aspirin and length of stay. Pediatrics. 2019;313(11):419-1563.
4. Schmidt W, Volkov K, et al. Pharmacist-led medication review and chronic pain scores. Ann Intern Med. 2017;283(9):871-1713.
5. Zhang V, Patel N, et al. Telemedicine follow-up and acute kidney injury. JAMA. 2018;245(4):612-1055.
6. Kaur B, Lindqvist M, et al. Pharmacist-led medication review and chronic pain scores. JAMA. 2010;191(5):501-923.
Appendices
Ethics approval: IRB-7606.